A computational protocol for the integration of the monotopic protein prostaglandin H2 synthase into a phospholipid bilayer.

Prostaglandin H2 synthase (PGHS) synthesizes PGH2, a prostaglandin precursor, from arachidonic acid and was the first monotopic enzyme to have its structure experimentally determined. Both isozymes of PGHS are inhibited by nonsteroidal antiinflammatory drugs, an important class of drugs that are the primary means of relieving pain and inflammation. Selectively inhibiting the second isozyme, PGHS-2, minimizes the gastrointestinal side-effects. This had been achieved by the new PGHS-2 selective NSAIDs (i.e., COX-2 inhibitors) but it has been recently suggested that they suffer from additional side-effects. The design of these drugs only made use of static structures from x-ray crystallographic experiments. Investigating the dynamics of both PGHS-1 and PGHS-2 using classical molecular dynamics is expected to generate new insight into the differences in behavior between the isozymes, and therefore may allow improved PGHS-2 selective inhibitors to be designed. We describe a molecular dynamics protocol that integrates PGHS monomers into phospholipid bilayers, thereby producing in silico atomistic models of the PGHS system. Our protocol exploits the vacuum created beneath the protein when several lipids are removed from the top leaflet of the bilayer. The protein integrates into the bilayer during the first 5 ns in a repeatable process. The integrated PGHS monomer is stable and forms multiple hydrogen bonds between the phosphate groups of the lipids and conserved basic residues (Arg, Lys) on the protein. These interactions stabilize the system and are similar to interactions observed for transmembrane proteins.

[1]  Carol Coupland,et al.  Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis , 2005, BMJ : British Medical Journal.

[2]  J. Otto,et al.  Photolabeling of Prostaglandin Endoperoxide H Synthase-1 with 3-Trifluoro-3-(m-Iiodophenyl)diazirine as a Probe of Membrane Association and the Cyclooxygenase Active Site (*) , 1996, The Journal of Biological Chemistry.

[3]  J. Chow,et al.  Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2 , 1996, Nature Structural Biology.

[4]  Raymond C Stevens,et al.  Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling , 2002, Science.

[5]  A. Mulichak,et al.  The structure of mammalian cyclooxygenases. , 2003, Annual review of biophysics and biomolecular structure.

[6]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[7]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[8]  William L. Smith,et al.  The Membrane Binding Domains of Prostaglandin Endoperoxide H Synthases 1 and 2 , 1999, The Journal of Biological Chemistry.

[9]  K. Seibert,et al.  Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Swinney,et al.  The Dynamics of Prostaglandin H Synthases , 1998, The Journal of Biological Chemistry.

[11]  Benoît Roux,et al.  Anchoring of a monotopic membrane protein: the binding of prostaglandin H2 synthase-1 to the surface of a phospholipid bilayer , 2000, European Biophysics Journal.

[12]  R. Garavito,et al.  Cyclooxygenases: structural, cellular, and molecular biology. , 2000, Annual review of biochemistry.

[13]  M. Hamberg,et al.  On the mechanism of the biosynthesis of prostaglandins E-1 and F-1-alpha. , 1967, The Journal of biological chemistry.

[14]  W. A. van der Donk,et al.  Comparison of the properties of prostaglandin H synthase-1 and -2. , 2003, Progress in lipid research.

[15]  K. Schulten,et al.  Computational studies of membrane channels. , 2004, Structure.

[16]  R. Kurumbail,et al.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents , 1996, Nature.

[17]  K. Schulten,et al.  Simulated (Un)Binding of Arachidonic Acid in the Cyclooxygenase site of Prostaglandin H2 Synthase-1 , 2000 .

[18]  R. Kurumbail,et al.  A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. , 2001, The Biochemical journal.

[19]  G. Blobel,et al.  Intracellular protein topogenesis. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[20]  G. Schulz,et al.  Structure and function of a squalene cyclase. , 1997, Science.

[21]  K. Schulten,et al.  Steered molecular dynamics and mechanical functions of proteins. , 2001, Current opinion in structural biology.

[22]  Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Gierse,et al.  A Single Amino Acid Difference between Cyclooxygenase-1 (COX-1) and −2 (COX-2) Reverses the Selectivity of COX-2 Specific Inhibitors* , 1996, The Journal of Biological Chemistry.

[24]  Martin B Ulmschneider,et al.  Properties of integral membrane protein structures: Derivation of an implicit membrane potential , 2005, Proteins.

[25]  R. Botting,et al.  Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition , 2004, Pharmacological Reviews.

[26]  E. Goetzl,et al.  Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases 1 , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  Andrea Mattevi,et al.  Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders , 2002, Nature Structural Biology.

[28]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[29]  M. Sansom,et al.  Lipid-protein interactions of integral membrane proteins: a comparative simulation study. , 2004, Biophysical journal.

[30]  K. Seibert,et al.  Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[31]  P. Loll,et al.  Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations. , 2001, Biochemistry.

[32]  Ke-He Ruan,et al.  Role of Val509 in Time-dependent Inhibition of Human Prostaglandin H Synthase-2 Cyclooxygenase Activity by Isoform-selective Agents* , 1996, The Journal of Biological Chemistry.

[33]  P. Loll,et al.  The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1 , 1994, Nature.

[34]  C. Bayly,et al.  Conversion of Prostaglandin G/H Synthase-1 into an Enzyme Sensitive to PGHS-2-selective Inhibitors by a Double His513 → Arg and Ile523 → Val Mutation* , 1997, The Journal of Biological Chemistry.

[35]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[36]  Laxmikant V. Kale,et al.  NAMD2: Greater Scalability for Parallel Molecular Dynamics , 1999 .

[37]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[38]  R. Kurumbail,et al.  Cyclooxygenase enzymes: catalysis and inhibition. , 2001, Current opinion in structural biology.

[39]  J. Mitchell,et al.  Cyclooxygenase-3 (COX-3): Filling in the gaps toward a COX continuum? , 2002, Proceedings of the National Academy of Sciences of the United States of America.